TP53 and cancer: In this review we discuss the current and emerging therapeutic strategies against mutant-p53-driven cancers based on small molecule re-activators, gene editing technologies (introduction of WT gene or CRISPR/Cas mediated corrections) and T cell immunotherapy (Figure 1).